Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646737 | 0.91 | KDM4E (0.62) | KDM4EADRB2ADRB1FFAR1GAA | |
| SCHEMBL1745247 | 0.84 | FFAR1 (0.72) | FFAR1FFAR4TDP1POLB | |
| SCHEMBL15679198 | 0.84 | FFAR1 (0.60) | ADRB2ADRB1FFAR1FFAR4GAA | |
| SCHEMBL1747136 | 0.84 | FFAR1 (0.72) | FFAR1FFAR4TDP1POLB | |
| SCHEMBL4255258 | 0.83 | MAOB (0.60) | ADRB2ADRB1FFAR1FFAR4 | |
| SCHEMBL2828491 | 0.83 | FFAR1 (0.71) | ADRB2ADRB1FFAR1FFAR4POLB | |
| SCHEMBL1745141 | 0.83 | FFAR1 (0.58) | ADRB2ADRB1FFAR1FFAR4GAA | |
| SCHEMBL1745397 | 0.83 | FFAR1 (0.58) | ADRB2ADRB1FFAR1FFAR4MAPT | |
| SCHEMBL1745363 | 0.83 | FFAR1 (0.58) | ADRB2ADRB1FFAR1FFAR4MAPT | |
| SCHEMBL1587089 | 0.82 | EPHX2 (0.60) | ADRB2ADRB1FFAR1FFAR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1740540-A1 | PHENYL ACETAMIDES | Bayer HealthCare AG (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2005103001-A1 | PHENYL ACETAMIDES | BAYER HEALTHCARE AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1572628-A1 | ISOPHTALIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052839-A1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | LTC4S, LTB4R2, LTB4R | KDM4E 1139/4885ADRB2 184/4885ADRB1 179/4885 |
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | KDM4E 4557/4885ADRB2 364/4885ADRB1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.